3 results
Approved WMOCompleted
To determine the efficacy and safety of adding transdermal nitroglycerin to first line chemotherapy for advanced NSCLC.
Approved WMOCompleted
To determine the activity (as measured by objective response rate by RECIST1.1) of monalizumab and trastuzumab in patients with metastatic HER2-positive breast cancer.
Approved WMORecruiting
To determine the median progression-free survival (PFS) and R0/1 secondary resection rate upon induction systemic treatment in colorectal cancer patients with initially unresectable liver-only metastases, stratified by RAS and BRAF tumor mutation…